Clovis Oncology Archives -

New price gets Clovis’ PARP inhibitor on the CDF

https://pharmaphorum.com/news/new-price-gets-clovis-parp-inhibitor-on-the-cdf/

Relief for GSK as Tesaro’s Zejula hits the mark in ovarian cancer

https://pharmaphorum.com/news/relief-for-gsk-as-tesaros-zejula-hits-the-mark-in-ovarian-cancer/

AZ/Merck & Co reveal data supporting PARP drug in prostate cancer

https://pharmaphorum.com/news/az-merck-co-reveal-data-supporting-parp-drug-in-prostate-cancer/

Janssen CAR-T is Priority Medicine in EU, and more

https://pharmaphorum.com/views-analysis-oncology/janssen-car-t-is-priority-medicine-in-eu-and-more/

Dreaming big with small molecules

https://pharmaphorum.com/views-analysis-oncology/dreaming-big-small-molecules/

Clovis hopes to get ahead of rivals in prostate cancer with Rubraca

https://pharmaphorum.com/news/clovis-hopes-to-get-ahead-of-rivals-in-prostate-cancer-with-rubraca/

Tesaro stock rockets as rumours of Roche takeover abound

https://pharmaphorum.com/news/tesaro-stock-rockets-roche-takeover-abound/

Clovis’ PARP drug gets new US ovarian cancer use

https://pharmaphorum.com/news/clovis-parp-drug-gets-new-us-ovarian-cancer-use/

Clovis’ Rubraca close to EU approval in ovarian cancer

https://pharmaphorum.com/oncology/clovis-rubraca-close-eu-approval-ovarian-cancer/

Search